GemPharmatech (SH:688046) GUOTAI HAITONG SECURITIES·2026-03-13 09:42Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with a compound annual growth rate (CAGR) of 17.6% [4][39]. - Net profit attributable to the parent company is expected to increase from 159 million CNY in 2023 to 205 million CNY in 2027, with a significant growth of 31.5% in 2025 [4][42]. - Earnings per share (EPS) is forecasted to rise from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][42]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive revenue growth [17][27]. - The commercialized mouse model business is the cornerstone, with revenue growth supported by an increase in high-end product sales and improved gross margins [22][25]. - The pharmacodynamic service segment is expected to become a significant growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company reported overseas revenue of 1.07 billion CNY in the first three quarters of 2025, marking a year-on-year increase of 23.62%, with a notable 63.97% growth in Q3 [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive future revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to long-term growth potential [33][34]. Profitability Forecast and Investment Recommendations - Revenue is projected to grow steadily, with expectations of 9.34 billion CNY in 2026 and 10.99 billion CNY in 2027, maintaining a growth rate of 17.7% and 17.6% respectively [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services will enhance profitability over time [10][42]. - Based on comparable company valuations, a price-to-earnings (PE) ratio of 55 times for 2026 is recommended, leading to a target price of 23.65 CNY [10][40][42].